3.連結財務諸表及び主な注記
(1)連結貸借対照表
| | (単位:千円) |
| 前連結会計年度 (2024年3月31日) | 当連結会計年度 (2025年3月31日) |
資産の部 | | |
流動資産 | | |
現金及び預金 | 2,939,057 | 2,823,367 |
売掛金 | 421,337 | 463,933 |
有価証券 | 3,627,800 | 1,118,245 |
商品及び製品 | 74,234 | 132,991 |
仕掛品 | 58,502 | 61,118 |
原材料及び貯蔵品 | 115,404 | 76,248 |
その他 | 163,286 | 220,821 |
貸倒引当金 | △284 | △283 |
流動資産合計 | 7,399,338 | 4,896,441 |
固定資産 | | |
有形固定資産 | | |
建物及び構築物 | 57,937 | 58,819 |
減価償却累計額 | △26,918 | △31,407 |
建物及び構築物(純額) | 31,019 | 27,411 |
機械装置及び運搬具 | 168,131 | 199,729 |
減価償却累計額 | △33,011 | △57,552 |
機械装置及び運搬具(純額) | 135,119 | 142,176 |
工具、器具及び備品 | 71,843 | 124,947 |
減価償却累計額 | △38,391 | △52,823 |
工具、器具及び備品(純額) | 33,452 | 72,124 |
有形固定資産合計 | 199,590 | 241,713 |
無形固定資産 | | |
のれん | 10,852 | 8,139 |
その他 | 13,364 | 18,699 |
無形固定資産合計 | 24,216 | 26,838 |
投資その他の資産 | | |
投資有価証券 | 1,381,921 | 4,403,537 |
繰延税金資産 | - | 55,322 |
その他 | 62,850 | 55,539 |
貸倒引当金 | △15,290 | △8,637 |
投資その他の資産合計 | 1,429,480 | 4,505,762 |
固定資産合計 | 1,653,288 | 4,774,314 |
資産合計 | 9,052,627 | 9,670,755 |
| | (単位:千円) |
| 前連結会計年度 (2024年3月31日) | 当連結会計年度 (2025年3月31日) |
負債の部 | | |
流動負債 | | |
買掛金 | 170,107 | 131,109 |
未払金 | 58,192 | 101,159 |
未払法人税等 | 27,157 | 24,796 |
契約負債 | 108,733 | 42,437 |
前受金 | 73,014 | 113,602 |
賞与引当金 | 6,744 | 11,080 |
その他 | 234,453 | 216,399 |
流動負債合計 | 678,403 | 640,585 |
固定負債 | | |
繰延税金負債 | 53,660 | 35,206 |
資産除去債務 | 8,969 | 9,081 |
その他 | - | 935 |
固定負債合計 | 62,630 | 45,223 |
負債合計 | 741,033 | 685,808 |
純資産の部 | | |
株主資本 | | |
資本金 | 2,322,198 | 2,688,926 |
資本剰余金 | 6,380,081 | 6,244,884 |
利益剰余金 | △546,875 | 58,294 |
自己株式 | △916 | △916 |
株主資本合計 | 8,154,487 | 8,991,188 |
その他の包括利益累計額 | | |
その他有価証券評価差額金 | 135,651 | △13,677 |
為替換算調整勘定 | 18,034 | 7,435 |
その他の包括利益累計額合計 | 153,686 | △6,242 |
新株予約権 | 3,419 | - |
純資産合計 | 8,311,593 | 8,984,946 |
負債純資産合計 | 9,052,627 | 9,670,755 |
E2758549780株式会社リプロセルReproCELL Incorporated通期第1号参考様式 [日本基準](連結)Japan GAAPtrueCTECTE2024-04-012025-03-31FY2025-03-312023-04-012024-03-312024-03-311falsefalsefalse497802025-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember497802024-04-012025-03-31jpcrp_cor:ReportableSegmentsMember497802024-04-012025-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember497802024-03-31jpcrp_cor:ReportableSegmentsMember497802024-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember497802023-04-012024-03-31jpcrp_cor:ReportableSegmentsMember497802023-04-012024-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember497802025-03-31tse-acedjpfr-49780:ResearchSupportBusinessReportableSegmentsMember497802025-03-31tse-acedjpfr-49780:MedicalBusinessReportableSegmentsMember497802024-04-012025-03-31tse-acedjpfr-49780:ResearchSupportBusinessReportableSegmentsMember497802024-04-012025-03-31tse-acedjpfr-49780:MedicalBusinessReportableSegmentsMember497802024-03-31tse-acedjpfr-49780:ResearchSupportBusinessReportableSegmentsMember497802024-03-31tse-acedjpfr-49780:MedicalBusinessReportableSegmentsMember497802023-04-012024-03-31tse-acedjpfr-49780:ResearchSupportBusinessReportableSegmentsMember497802023-04-012024-03-31tse-acedjpfr-49780:MedicalBusinessReportableSegmentsMember497802025-03-31jpcrp_cor:ReconcilingItemsMember497802024-04-012025-03-31jpcrp_cor:ReconcilingItemsMember497802024-03-31jpcrp_cor:ReconcilingItemsMember497802023-04-012024-03-31jpcrp_cor:ReconcilingItemsMember497802025-03-31jpcrp_cor:ReportableSegmentsMember497802024-03-31jppfs_cor:SubscriptionRightsToSharesMember497802023-04-012024-03-31jppfs_cor:ShareholdersEquityMember497802023-04-012024-03-31jppfs_cor:CapitalStockMember497802025-03-31jppfs_cor:ShareholdersEquityMember497802025-03-31jppfs_cor:CapitalStockMember497802025-03-31jppfs_cor:CapitalSurplusMember497802025-03-31jppfs_cor:RetainedEarningsMember497802023-04-012024-03-31jppfs_cor:CapitalSurplusMember497802023-04-012024-03-31jppfs_cor:RetainedEarningsMember497802023-04-012024-03-31jppfs_cor:TreasuryStockMember497802023-04-012024-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember497802023-04-012024-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember497802023-04-012024-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember497802023-04-012024-03-31jppfs_cor:SubscriptionRightsToSharesMember497802023-03-31jppfs_cor:ShareholdersEquityMember497802023-03-31jppfs_cor:CapitalStockMember497802023-03-31jppfs_cor:CapitalSurplusMember497802023-03-31jppfs_cor:RetainedEarningsMember497802023-03-31jppfs_cor:TreasuryStockMember497802023-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember497802023-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember497802024-03-31jppfs_cor:CapitalSurplusMember497802025-03-31jppfs_cor:TreasuryStockMember497802025-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember497802025-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember497802025-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember497802025-03-31jppfs_cor:SubscriptionRightsToSharesMember497802024-04-012025-03-31jppfs_cor:ShareholdersEquityMember497802024-04-012025-03-31jppfs_cor:CapitalStockMember497802024-04-012025-03-31jppfs_cor:CapitalSurplusMember497802024-04-012025-03-31jppfs_cor:RetainedEarningsMember497802024-04-012025-03-31jppfs_cor:TreasuryStockMember497802024-04-012025-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember497802024-04-012025-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember497802024-04-012025-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember497802024-04-012025-03-31jppfs_cor:SubscriptionRightsToSharesMember497802024-03-31jppfs_cor:ShareholdersEquityMember497802024-03-31jppfs_cor:CapitalStockMember497802024-03-31jppfs_cor:RetainedEarningsMember497802024-03-31jppfs_cor:TreasuryStockMember497802024-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember497802024-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember497802024-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember497802023-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember497802023-03-31jppfs_cor:SubscriptionRightsToSharesMember497802025-05-14497802025-03-31497802024-04-012025-03-31497802024-03-31497802023-04-012024-03-31497802023-03-31xbrli:pureiso4217:JPY